Literature DB >> 28350522

The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.

Fen Jiang1, Jong-Yeol Choi1, Ju-Hyun Lee1, Sunae Ryu1, Ze-Won Park1, Jong-Gu Lee1, Han-Sung Na1, Seok-Yong Lee2, Woo-Yong Oh1, Myeon-Woo Chung1, Seung-Eun Choi1.   

Abstract

AIM: To investigate the combined effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin and its active metabolite simvastatin acid, in relation to CYP3A4 inhibition.
METHODS: We conducted a single-dose pharmacokinetic study of simvastatin in 26 healthy volunteers screened for their SLCO1B1 c.521T>C and ABCB1 c.1236C>T-2677G>T-3435C>T genotypes, with and without amlodipine pretreatment. The genetic effects and drug-interaction effect on simvastatin pharmacokinetic parameters were analyzed using a linear-mixed model.
RESULTS: The SLCO1B1 c.521T>C variant significantly increased exposure to simvastatin acid by around 40% (p < 0.05), similar to that caused by the amlodipine pretreatment. The ABCB1 gene showed no influence on exposure to simvastatin or simvastatin acid.
CONCLUSION: Only SLCO1B1, not ABCB1 genotype, is likely to be associated with simvastatin-induced myopathy. SLCO1B1 genotyping may be particularly beneficial in simvastatin users who are co-administered CYP3A4 inhibitors.

Entities:  

Keywords:  ABCB1; SLCO1B1; amlodipine; pharmacogenomics; pharmacokinetics; simvastatin

Mesh:

Substances:

Year:  2017        PMID: 28350522     DOI: 10.2217/pgs-2016-0199

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  11 in total

1.  Physiologically Based Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug-Drug Interaction Potentials.

Authors:  Su-Jin Rhee; Hyun A Lee; Soyoung Lee; Eunwoo Kim; Inseung Jeon; Im-Sook Song; Kyung-Sang Yu
Journal:  Pharm Res       Date:  2018-10-15       Impact factor: 4.200

Review 2.  Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy.

Authors:  Baron Bechtold; John Clarke
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-01-20       Impact factor: 4.481

3.  MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy.

Authors:  Yong Tian; Junhong Wang; Yanxiao Liu; Xiangguang Luo; Ziying Yao; Xinjun Wang; Yuanyuan Zhang; Cheng Xu; Xiaoyu Zhao
Journal:  BMC Med Genomics       Date:  2021-03-17       Impact factor: 3.063

4.  The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies.

Authors:  Abdallah Abu Mellal; Nadia Hussain; Amira Sa Said
Journal:  Ther Clin Risk Manag       Date:  2019-07-23       Impact factor: 2.423

5.  The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation.

Authors:  Yi Wu; Fang Fang; Zhaowen Wang; Peihao Wen; Junwei Fan
Journal:  Eur J Clin Pharmacol       Date:  2021-01-02       Impact factor: 2.953

6.  Severe adverse cutaneous reactions induced by gefitinib combined with antihypertensive and antihyperlipidemic drugs in lung cancer: a case report.

Authors:  Xiao Shen; Guorong Fan; Gaolin Liu; Fan Wang; Qi Li; Xinyan Liu; Hong Zhu; Ying Zhu; Jiguang Lu; Shuowen Wang
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

7.  Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4.

Authors:  Meng Meng; Xin Li; Xiuwen Zhang; Bin Sun
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

8.  The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial.

Authors:  Rafael B R León-Cachón; Aileen-Diane Bamford; Irene Meester; Hugo Alberto Barrera-Saldaña; Magdalena Gómez-Silva; María F García Bustos
Journal:  Sci Rep       Date:  2020-06-01       Impact factor: 4.379

Review 9.  Drug-drug-gene interactions and adverse drug reactions.

Authors:  Mustafa Adnan Malki; Ewan Robert Pearson
Journal:  Pharmacogenomics J       Date:  2019-12-03       Impact factor: 3.550

Review 10.  Pharmacogenetics of Statin-Induced Myotoxicity.

Authors:  Ping Siu Kee; Paul Ken Leong Chin; Martin A Kennedy; Simran D S Maggo
Journal:  Front Genet       Date:  2020-10-16       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.